Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Australian Clinical LabsASX:ACL -0.83%56 PS Ratio is 0.61 as of Aug. 01, 2026, which is 24% below its 10-year median of 0.80. GuruFocus rates ASX:ACL with a GF Score™ of 56/100 and a GF Value™ of A$3.06 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Australian Clinical Labs ranks better than 90.5% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Australian Clinical Labs's share price is A$2.38.
Australian Clinical Labs's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$3.93. Hence, Australian Clinical Labs's PS Ratio for today is 0.61.
The historical rank and industry rank for Australian Clinical Labs's PS Ratio or its related term are showing as below:
ASX:ACL'
s PS Ratio Range Over the Past 10 Years
Min: 0.49 Med: 0.8 Max: 1.47
Current: 0.6
During the past 6 years, Australian Clinical Labs's highest PS Ratio was 1.47. The lowest was 0.49. And the median was 0.80.
ASX:ACL's PS Ratio is ranked better than 90.5% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.755
vs ASX:ACL: 0.60
During the past 6 years, Australian Clinical Labs's highest 3-Year average Revenue per Share Growth Rate was -6.40% per year. The lowest was -7.60% per year. And the median was -7.00% per year.
Australian Clinical Labs (ASX:ACL) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Australian Clinical Labs's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Australian Clinical Labs PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's PS Ratio distribution charts can be found below:
* The bar in red indicates where Australian Clinical Labs's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Australian Clinical Labs's Share Price of today is A$2.38.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Australian Clinical Labs's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$3.93.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Australian Clinical Labs (ASX:ACL) has a PS Ratio of 0.61 as of Aug. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Australian Clinical Labs and its competitors. This is 24% below median its historical median of 0.80. Over the past decade, Australian Clinical Labs' PS Ratio has ranged from 0.49 to 1.47. According to the industry distribution chart, Australian Clinical Labs ranks #19 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 9.5%.
Is Australian Clinical Labs' PS Ratio too high?
Australian Clinical Labs' current PS Ratio of 0.61 is 24% below median its 10-year median of 0.80. Over the past 10 years, this metric has ranged from a low of 0.49 to a high of 1.47. The Medical Diagnostics & Research industry median PS Ratio is 2.76. Australian Clinical Labs' value of 0.61 is 77.9% below this industry median. Based on the distribution chart, Australian Clinical Labs ranks #19 out of 200 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Australian Clinical Labs has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Australian Clinical Labs' PS Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Australian Clinical Labs ranks #19 out of 200 companies for PS Ratio. This places Australian Clinical Labs in the top 10% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.76. Australian Clinical Labs' value of 0.61 is 77.9% below this benchmark. Historically, Australian Clinical Labs' own PS Ratio has ranged from 0.49 to 1.47 over the past decade. While the company's 10-year median is 0.80 vs. the industry median of 2.76, Australian Clinical Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.76, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Australian Clinical Labs's current PS Ratio of 0.61 is 77.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Australian Clinical Labs and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Australian Clinical Labs's current PS Ratio is 0.61, which is 24% below median its own 10-year median of 0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australian Clinical Labs stock overvalued right now?
Based on GuruFocus' analysis, Australian Clinical Labs (ASX:ACL) is currently considered Modestly Undervalued. The stock's GF Value™ is A$3.06, compared to a current price of A$2.38 — trading 22.2% below its estimated fair value. The current PS Ratio is 0.61, which is 24% below median its 10-year median of 0.80 and 77.9% below the Medical Diagnostics & Research industry median of 2.76. Australian Clinical Labs' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Australian Clinical Labs (ASX:ACL), the current PS Ratio is 0.61 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?
Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued.
The current stock price of A$2.38 is trading 22.2% below its estimated GF Value™ of A$3.06.
GuruFocus considers Australian Clinical Labs to be Modestly Undervalued.
Key valuation signals for ASX:ACL:
PS Ratio: 0.61 (24% below median its 10-year median of 0.80)
GF Value™: A$3.06 vs. price of A$2.38 (22.2% below fair value)
Industry Position: 77.9% below the Medical Diagnostics & Research median (#19 of 200)
No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
56GF Score
Get the complete analysis for ASX:ACL
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ACL has been successfully added to your 
